JP2022535406A5 - - Google Patents
Info
- Publication number
- JP2022535406A5 JP2022535406A5 JP2021571834A JP2021571834A JP2022535406A5 JP 2022535406 A5 JP2022535406 A5 JP 2022535406A5 JP 2021571834 A JP2021571834 A JP 2021571834A JP 2021571834 A JP2021571834 A JP 2021571834A JP 2022535406 A5 JP2022535406 A5 JP 2022535406A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- days
- period
- dose
- subsequent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858076P | 2019-06-06 | 2019-06-06 | |
| US62/858,076 | 2019-06-06 | ||
| EP19193850.5 | 2019-08-27 | ||
| EP19193850 | 2019-08-27 | ||
| PCT/EP2020/065639 WO2020245365A1 (en) | 2019-06-06 | 2020-06-05 | Methods of treating cancer using prmt5 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535406A JP2022535406A (ja) | 2022-08-08 |
| JP2022535406A5 true JP2022535406A5 (enExample) | 2023-06-13 |
| JP7590351B2 JP7590351B2 (ja) | 2024-11-26 |
Family
ID=70922068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571834A Active JP7590351B2 (ja) | 2019-06-06 | 2020-06-05 | Ｐｒｍｔ５阻害剤を使用した癌の治療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11571437B2 (enExample) |
| EP (1) | EP3980019A1 (enExample) |
| JP (1) | JP7590351B2 (enExample) |
| KR (1) | KR20220017989A (enExample) |
| CN (1) | CN113966232A (enExample) |
| AU (1) | AU2020286961A1 (enExample) |
| BR (1) | BR112021024469A2 (enExample) |
| CA (1) | CA3142825A1 (enExample) |
| IL (1) | IL288665A (enExample) |
| JO (1) | JOP20210320A1 (enExample) |
| MA (1) | MA56095A (enExample) |
| MX (1) | MX2021014944A (enExample) |
| PH (1) | PH12021552841A1 (enExample) |
| SG (1) | SG11202112439YA (enExample) |
| TW (1) | TW202112375A (enExample) |
| WO (1) | WO2020245365A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153161A1 (en) * | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CN115161341B (zh) * | 2022-06-10 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| JP2005527502A (ja) | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
| EP1694642A4 (en) | 2003-12-19 | 2010-10-06 | Koronis Pharmaceuticals Inc | MUTAGENIC HETEROCYCLES |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| EP2043635A2 (en) | 2006-06-29 | 2009-04-08 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| KR20120113228A (ko) | 2009-12-18 | 2012-10-12 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 베타 세포 복제 촉진 화합물 및 그 사용 방법 |
| EP2646455A4 (en) | 2010-12-03 | 2014-04-02 | Epizyme Inc | Modulators of histone methyltransferase, and methods of use thereof |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| JP5906253B2 (ja) | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| CA2942833A1 (en) * | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| TN2019000087A1 (en) | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| TN2019000212A1 (en) | 2017-02-27 | 2021-01-07 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| US11059850B2 (en) | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
-
2020
- 2020-06-04 TW TW109118748A patent/TW202112375A/zh unknown
- 2020-06-05 SG SG11202112439YA patent/SG11202112439YA/en unknown
- 2020-06-05 US US16/893,477 patent/US11571437B2/en active Active
- 2020-06-05 MX MX2021014944A patent/MX2021014944A/es unknown
- 2020-06-05 EP EP20729788.8A patent/EP3980019A1/en active Pending
- 2020-06-05 PH PH1/2021/552841A patent/PH12021552841A1/en unknown
- 2020-06-05 MA MA056095A patent/MA56095A/fr unknown
- 2020-06-05 WO PCT/EP2020/065639 patent/WO2020245365A1/en not_active Ceased
- 2020-06-05 JP JP2021571834A patent/JP7590351B2/ja active Active
- 2020-06-05 CA CA3142825A patent/CA3142825A1/en active Pending
- 2020-06-05 CN CN202080043244.1A patent/CN113966232A/zh active Pending
- 2020-06-05 AU AU2020286961A patent/AU2020286961A1/en not_active Abandoned
- 2020-06-05 KR KR1020227000036A patent/KR20220017989A/ko not_active Ceased
- 2020-06-05 BR BR112021024469A patent/BR112021024469A2/pt unknown
-
2021
- 2021-12-01 JO JOP/2021/0320A patent/JOP20210320A1/ar unknown
- 2021-12-05 IL IL288665A patent/IL288665A/en unknown
-
2023
- 2023-01-26 US US18/160,246 patent/US20230241087A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI854573B (zh) | 藥物組合物、其用途及癌症的治療方法 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2024526145A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2022535406A5 (enExample) | ||
| JP6761852B2 (ja) | がん治療 | |
| JP2024133474A5 (enExample) | ||
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2015510908A (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2015513315A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP2015517523A5 (enExample) | ||
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2007500240A5 (enExample) | ||
| JP2007500240A (ja) | Ａｂｔ−７５１による持続投与レジメン | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 | |
| TW202339726A (zh) | 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179 | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax |